CVMD IMED AstraZeneca R&D Mölndal, Mölndal, Sweden.
Personalised Healthcare and Biomarkers, AstraZeneca R&D Mölndal, Mölndal, Sweden.
J Thromb Haemost. 2017 Apr;15(4):758-769. doi: 10.1111/jth.13641. Epub 2017 Feb 28.
Essentials Fibrinolysis inhibitors are localized in advanced atheroma by immunohistology of endarterectomies. Neovascular endothelium/neocapillaries show thrombin-activatable fibrinolysis inhibitor (TAFI). Macrophage areas show free plasminogen activator inhibitor (PAI-1), notably in the vulnerable part. Free PAI-1 and TAFI stabilize active plaque area by inhibition of fibrinolysis and inflammation.
Background Fibrinolysis plays an important role in destabilization of atherosclerotic plaques and is tightly regulated by specific inhibitors. Objective The fibrinolysis inhibitors plasminogen activator inhibitor type-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) were quantified and described in the morphological context of advanced carotid plaques American Heart Association VI-VIII to elucidate their role in plaque stability. Methods Immunohistochemistry in serial sections along the longitudinal axis of endarterectomies from patients with symptomatic carotid stenosis (n = 19) were studied using an antibody specific for free PAI-1 (I205), an antibody with high affinity for TAFI/TAFIa (CP17) and established antibodies for smooth muscle cells (α-actin), endothelial cells (von Willebrand factor [VWF]), macrophages (CD68) and platelets (CD42). Results PAI-1 and TAFI show a specific distribution in these advanced plaques with a maximum corresponding to the internal carotid artery (ICA). Free PAI-1 was mainly detected in macrophages and in intravascular thrombi, and TAFI in endothelial cells (ECs) but also macrophages. The one-way ANOVA analysis with Bonferroni's correction showed a significant increase of macrophages and ECs, TAFI and PAI-1 in areas with high neovascularization in endarterectomy sections corresponding to ICA. High Spearman factors for TAFI, PAI-1 and VWF indicate neovascularization as the main source of plasma proteins, transported by platelets into the atheroma (PAI-1) or expressed by ECs (TAFI). CD68 was highly associated with VWF, PAI-1 and especially TAFI, underlining the role of macrophages in fibrinolytic activity and inflammation. Conclusion The abundance of free PAI-1 and TAFI in the plaque may inhibit plasmin generation and thereby counteract plaque destabilization by fibrinolysis, cell migration and inflammation.
通过动脉内膜切除术的免疫组织化学研究,纤维蛋白溶解抑制剂定位于动脉粥样硬化晚期。新生血管内皮细胞/新毛细血管显示凝血酶激活的纤维蛋白溶解抑制剂 (TAFI)。巨噬细胞区域显示游离的纤溶酶原激活物抑制剂 (PAI-1),尤其是在易损部位。游离的 PAI-1 和 TAFI 通过抑制纤维蛋白溶解和炎症稳定活性斑块区域。
背景纤维蛋白溶解在动脉粥样硬化斑块的不稳定中起着重要作用,并且受到特定抑制剂的严格调节。目的定量描述纤维蛋白溶解抑制剂纤溶酶原激活物抑制剂 1 (PAI-1) 和凝血酶激活的纤维蛋白溶解抑制剂 (TAFI) 在动脉粥样硬化晚期斑块中的形态学背景下,以阐明其在斑块稳定性中的作用。方法对有症状颈动脉狭窄患者的动脉内膜切除术的沿长轴的连续切片进行免疫组织化学研究(n = 19),使用针对游离 PAI-1 (I205) 的抗体、针对 TAFI/TAFIa (CP17) 的高亲和力抗体以及针对平滑肌细胞 (α-肌动蛋白) 的已建立抗体。)、内皮细胞(血管性血友病因子 [VWF])、巨噬细胞(CD68)和血小板(CD42)。结果 PAI-1 和 TAFI 在这些晚期斑块中具有特定的分布,最大值对应颈内动脉 (ICA)。游离 PAI-1 主要在巨噬细胞和血管内血栓中检测到,TAFI 在血管内皮细胞 (EC) 中也检测到巨噬细胞。Bonferroni 校正的单因素方差分析显示,在内膜切除术切片中,与 ICA 相对应的高新生血管化区域的巨噬细胞和 EC、TAFI 和 PAI-1 显著增加。TAFI、PAI-1 和 VWF 的高 Spearman 因子表明,新生血管化是血浆蛋白的主要来源,由血小板运送到动脉粥样硬化中(PAI-1)或由 EC 表达(TAFI)。CD68 与 VWF、PAI-1 尤其是 TAFI 高度相关,这强调了巨噬细胞在纤维蛋白溶解活性和炎症中的作用。结论斑块中游离 PAI-1 和 TAFI 的丰度可能会抑制纤溶酶的产生,从而通过纤维蛋白溶解、细胞迁移和炎症来抑制斑块的不稳定。